Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CTFH and Insilico Form $200 Million AI-Based Drug Discovery Partnership

publication date: Oct 9, 2019

Jiangsu Chia Tai Fenghai Pharma (CTFH) signed a $200 million agreement with Insilico Medicine, an AI drug discovery company headquartered in Hong Kong, to discover two triple-negative breast cancer candidates, aiming at previously undruggable targets. In September, Insilico raised $37 million from China investors after publishing an article in Nature Biotechnology showing its AI-platform could generate, synthesize and preclinically validate a series of compounds in 46 days. CTFH, which said it hopes the collaboration will become a long-term relationship, will make milestone payments and pay royalties on the candidates. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital